Embolic Protection Flops for TAVR

ACC Conference Reporter

TCT 2016 | Washington, DC — An embolic protection device deployed during transcatheter aortic valve replacement (TAVR) caught plenty of material but without any impact on subclinical or clinical outcomes, the randomized controlled SENTINEL trial showed. Read More >>>

Keywords: Transcatheter Cardiovascular Therapeutics


< Back to Listings